LiGeR HN1 Meets Survival and Response Endpoints
Genmab reported on 28 October that first-line petosemtamab plus pembrolizumab met both Phase III LiGeR-HN1 primary endpoints against pembrolizumab alone in PD-L1-positive recurrent or metastatic head-and-neck cancer. Overall-survival HR was 0.50, but absolute survival…
